Cited by 127Genetics, Aging, and Longevity in Model OrganismsSirtuins and Resveratrol in MedicineTelomeres, Telomerase, and Senescence

Drugs that modulate aging: the promising yet difficult path ahead

Open access
Kennedy, Brian K., Pennypacker, Juniper K.·2014·Translational research

Abstract

Once a backwater in medical sciences, aging research has emerged and now threatens to take the forefront. This dramatic change of stature is driven from 3 major events. First and foremost, the world is rapidly getting old. Never before have we lived in a demographic environment like today, and the trends will continue such that 20% percent of the global population of 9 billion will be over the age of 60 by 2050. Given current trends of sharply increasing chronic disease incidence, economic disaster from the impending silver tsunami may be ahead. A second major driver on the rise is the dramatic progress that aging research has made using invertebrate models such as worms, flies, and yeast. Genetic approaches using these organisms have led to hundreds of aging genes and, perhaps surprisingly, strong evidence of evolutionary conservation among longevity pathways between disparate species, including mammals. Current studies suggest that this conservation may extend to humans. Finally, small molecules such as rapamycin and resveratrol have been identified that slow aging in model organisms, although only rapamycin to date impacts longevity in mice. The potential now exists to delay human aging, whether it is through known classes of small molecules or a plethora of emerging ones. But how can a drug that slows aging become approved and make it to market when aging is not defined as a disease. Here, we discuss the strategies to translate discoveries from aging research into drugs. Will aging research lead to novel therapies toward chronic disease, prevention of disease or be targeted directly at extending lifespan?

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2013.11.007

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kennedy, B. K., & Pennypacker, J. K.
Affiliations
Buck Institute for Research on Aging (US)
Corresponding author
Kennedy, Brian K.
Venue
Translational research
Publisher
Elsevier BV
Published
2014-05
Volume
163
Issue
5
Pages
456-465
ISSN
  • 1878-1810 (ISSN-L)
  • 1931-5244
OpenAlex
W2111463058
Cited by
127
References
123
Citations by year
2026: 1 · 2025: 10 · 2024: 5 · 2023: 8 · 2022: 10 · 2021: 8 · 2020: 14 · 2019: 15 · 2018: 10 · 2017: 8 · 2016: 11 · 2015: 12 · 2014: 13 · 2013: 2
FWCI
0.78
Type
journal article
Language
en
Open access
Locations
  • Translational research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Aging (R01AG033373)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
aging, anti-aging drugs, longevity, aging research, rapamycin, resveratrol, aging-related genes, small molecules, drug development, lifespan extension, chronic disease, invertebrate models
MeSH terms
Aging, Animals, Gene Expression Regulation, Humans, United States, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review